Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma [version 1; referees: 2 approved]

• Main Authors: Michael W. Bishop, Katherine A. Janeway
• Format: Article
• Language: English
• Published: F1000 Research Ltd 2016-07-01
• Series: F1000Research
• Subjects: Cancer Therapeutics; Cell Growth & Division; Cell Signaling; Medical Genetics; Pediatric Oncology; Sarcomas
• Online Access: http://f1000research.com/articles/5-1590/v1
• ISSN: 2046-1402

Patients with metastatic and recurrent osteosarcoma fare poorly, and new therapeutic strategies are needed to improve survival. Several recent complementary genomic and pathway analyses of both murine and human osteosarcoma have revealed common aberrations of the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway in osteosarcoma. Preclinical data demonstrate that inhibition of PI3K and mTOR with either a combination of single agents or dual inhibiting compounds can decrease cell proliferation and induce cell cycle arrest and apoptosis. With a lack of available clinical agents active in osteosarcoma, PI3K/mTOR inhibition represents a potential vulnerability in osteosarcoma that warrants clinical investigation.